ELMWOOD PARK, N.J.--(BUSINESS WIRE)--BioReference Laboratories, Inc. (NASDAQ: BRLI) announced today that it is now offering next generation sequencing testing for Dilated Cardiomyopathy (DCM) conditions through its GeneDx laboratory. GeneDx is the first commercial laboratory in the country, possibly the world, to offer clinical testing based on next generation sequencing, full genome sequencing provided through high-speed, high throughput computer-based analysis. After nearly two years of development, GeneDx has designed software that enables the laboratory to provide focused, multi-gene diagnostic analysis of complex cases spanning multiple genes. GeneDx first pioneered the use of this platform previously with its test for Hypertrophic Cardiomyopathy (HCM), which it began offering in September 2008.
